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Summary 
The mechanisms  that induce  T  cell tolerance to circulating self-proteins are still controversial, 
and both the deletion and selection ofautoreactive T  cells have been observed in the thymus of 
transgenic  mouse models.  To address the question  of the induction  of tolerance to circulating 
self-constituents,  a  T  cell receptor-transgenic  mouse specific for the  serum protein  imnmno- 
globulin  (Ig) y  and  (IgG2a  b) was generated.  The  choice of an allotype-specific T  cell also al- 
lowed the  generation  of transgenic  control  mice not  expressing the self-antigen.  It was found 
that the transgenic T  cells were not deleted in the thynms, did not become tolerant in the pe- 
riphery, and regulated the function ofy2ab-positive B cells as shown by the lack of IgG2a  b pro- 
tein in the serum of the transgenic mice. In spite of this activity, in vivo, the transgenic  T  cells 
did not  proliferate in vitro  in response to the allotype-specific peptide.  Interestingly,  antigen- 
specific T  cell proliferation could be restored if the transgenic nfice were previously challenged 
to induce  lgG2a  b responses. After this challenge,  IgG2a  b protein in the serum of the transgenic 
mice could be partially restored,  although still remaining much lower than in control mice.  In 
addition,  there  was a  dramatic  increase  in  serum  IgE levels,  suggesting  that  newly  generated 
~/2ab-secreting B  cells can be induced  to switch  to  lgE  in  the  presence  of allotype-specific T 
cells.  These  results  indicate  that  Ig-specific T  ceils may represent  a  late-acting form of T  cell 
help for the regulation of the IgG2a-to-IgE class switch. 
T 
olerance is the property by which  the inmmne system 
becomes  unresponsive  to  self-constituents,  and  it  can 
be achieved  either by clonal  deletion  or functional  silenc- 
ing  (anergy)  (for  reviews  see  references  1,  2).  The  toler- 
ance-inducing  capacity of three  major groups  of self-anti- 
gens--thymic  presented,  tissue  sequestered,  or  circulating 
proteins--has  been studied.  In the  thymus,  negative selec- 
tion of potentially autoreactive T  cells has been extensively 
investigated.  Indeed,  T  cells  recognizing  a  self-protein 
epitope  in  association  with  MHC  molecules  are  deleted 
during  the  T  cell  differentiation  process  (3-5).  In the  pe- 
riphery, anergy or clonal deletion of T  ceils specific for tis- 
sue-sequestered  self-antigens,  not  presented  in  the  thymus 
and  thus  evading  negative  selection,  has  also  been  shown 
(6).  On  the  other hand,  several examples of tissue-specific 
proteins that do not induce any thymic or peripheral toler- 
ance have recently been described (7-9).  In these studies, T 
cells specific for myelin basic protein or antigens expressed 
in  pancreas  13  islets,  induced  autoimnmnity  in  transgenic 
experimental  allergic  encephalomyelitis-  and  diabetes-sus- 
ceptible mice, respectively. 
Regarding circulating self-proteins, the mechanisms that 
induce  T  cell  tolerance  are  still  controversial.  It has  been 
observed that transgenic  mice expressing small amounts  of 
hen  egg lysozyme (10)  or  "physiological"  amounts  of hu- 
man  insulin  (11)  were tolerant  to these  antigens,  but mice 
expressing  a  soluble  transplantation  antigen  did  not  show 
any T  cell tolerance  (12).  However,  in all of these studies, 
T  cell functional  activity was investigated in vitro,  and the 
fate  of the  antigen-specific  T  cells  was  not  examined  in 
vivo.  Recently,  thymic  deletion  of transgenic  T  cells spe- 
cific for the fifth component of complement (C51  [a natural 
self-antigen  regulated  physiologically])  has  been  observed 
(13). 
In a different transgenic  mouse model,  antiidiotype-spe- 
cific T  cells were deleted in the thymus only if the idiotype 
was expressed within  the  thymus as a  transgene,  or by the 
injection  of nonphysiological  amounts  of Ig  (14).  When 
the  endogenous  idiotype  was  expressed  at  physiological 
levels,  positive selection  was observed in the  thynms  (15). 
Thus,  the  question  of how  the  inmmne  system  becomes 
tolerant  to  circulating  proteins,  and  in  particular  whether 
and  how  it  becomes  tolerant  to  its  own  Igs,  is  still  open. 
Finding  an  answer  to  it  could  help  us  to  understand 
tAbbreviations used in  this paper: C5,  fifth component  of complement; 
ELISPOT,  enzyme-linked  immunospot;  P,T,  reverse transcription; 
TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin 
nick end labeling. 
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diseases,  such as rheumatoid arthritis. 
The possibility that circulating lg-specific autoreactive T 
cells may be harmless for the  organism should be consid- 
ered.  In line with the hypothesis that B  cells  cannot prime 
virgin T  cells (16), it may be thought that most antiisotype 
virgin T  lymphocytes might develop  tolerance to  B  cells 
presenting epitopes of their own Ig (17).  However,  it has 
also been shown that, if correctly activated by CD4 + helper 
T  lymphocytes, B cells may acquire all of the costimulatory 
signals necessary,  to prime virgin T  cells (18). Furthermore, 
it has been recently demonstrated that, if activated via the B 
cell receptor, B cells transduce all of the signals necessary for 
virgin T  cell proliferation and lymphokine production (19). 
To study the fate of T  cells specific for Ig as circulating 
self-constituents,  we  have  generated  a  TCR-transgenic 
mouse model specific for the serum protein IgG2a  b. There 
were two reasons for the choice of this model: first,  an allo- 
type-specific T  cell would allow us to  generate transgenic 
control mice that do  not express  the  sel~Lantigen;  second, 
in the absence of tolerance induction, the fate orB cells af- 
ter the  interaction with  allotype-specific T  ceils  could be 
followed. 
In the  mouse model described in this study,  the  trans- 
genic T  cells are not deleted in the thymus, do not become 
tolerant in the periphery, and regulate the function ofy2a  ~- 
positive B  cells,  as shown by the lack of lgG2a  b protein in 
the serum of the transgenic mice. 
Interestingly,  when  the  animals'  imnmne  system  was 
challenged by immunization, the IgG2a  b protein in the se- 
rum remained much lower than in controls, and a dramatic 
increase in IgE was observed. This suggests that the y2a  ~- 
secreting B  cells can be  induced to  switch  to  IgE  in the 
presence of allotype-specific T  cells. 
Materials and Methods 
Mice.  BALB/c, DBA/2, and CD1 mice were purchased from 
Charles [Liver Laboratories,  Inc. (Willmington, MA) and bred in 
our  conventional animal  facility.  CB17  mice  were  purchased 
from the Jackson Laborato D, (Bar Harbor, ME). 
Construction of the  c*  Transgene.  The ix and [3  chains  of the 
TCK were both cloned from the B5  T  cell clone.  The a-rear- 
ranged coding cDNA (1,300 bp) was amplified by anchored PCR 
as  described  (20), cloned in the  XhoI-Sma[ restriction  sites of 
pGEM7zf (Promega  Corp.,  Madison,  WI), and sequenced.  The 
ohgonucleotides used were 5'TACTCGAGTCGACATCGATTT- 
TTTTTTTTTTTTTTY and  5'TACTCGAGTCGACATCGA- 
TY (used in 5') and 5'CTGTTTCAAAGCTTTTCTCGGTCA- 
ACGTGGY (used in 3'). The SalI-BamHl fragment containing 
the complete coding sequence for the ix chain was subcloned in 
the priSE3' transgenic vector (21). 
Construction of the ~  Transgene.  A  900-bp XhoI-Smal frag- 
ment  containing rearranged  V~I4/Df~I.I/Jf~2.5/C~2  sequences 
was generated by reverse  transcription (RT)  PCR,  cloned into 
pGEM7zf,  and sequenced.  The oligonucleotides used ~br the am- 
plification  were  5'GGTCGACTCGAGAAAGACCATCTT- 
GAACTATY (used in 5') and 5'GTTTRANSGENICTCTTC- 
AGGAATTTTTTTTCTTGACCY  (used in 3'). The P,.T-PC[L 
amplification cycle was perfomaed at the following conditions: 60 s 
at 94~  6(1 s at 60~  60 s at 72~  for 30 cycles and 1 cycle at 
72~  for 10 nfin to terminate the reaction.  The SalI-BamHI frag- 
ment was inserted  into the pHSE3'-transgenic vector.  The two 
XhoI-Xhol fragments, from pHSEYIX and pHSEY[3, correspond- 
ing to the ix and 13 chains, were used to produce transgenic mice. 
Generation of Transgenic Mice.  Transgenic mice were  gener- 
ated as described by Hogan et al. (22). DBA/2 (H-2  d)  X BALB/c 
(H-2  d)  mice were used as a source  of oocytes,  and the  injected 
eggs were implanted in pseudopregnant CD 1 females. Separate oe 
and [3 chain-transgenic mice were established, and the two lines 
were  then  bred  together  to  produce  mice  with  the  complete 
TC[L. These mice were crossed to BALB/c mice for three gener- 
ations (Tg+b -  mice). Tg+b  * were generated by breeding Tg+b  - 
male mice with CB17 females. 
Flow Cytometq,.  Single-cell suspensions of 106 thymocytes  or 
lymph node cells were pelleted and resuspended  in 50 btl of PBS 
with  5%  FCS  and  0.05%  sodium  azide  with  the  appropriate 
anmunts of antibodies and incubated for  3(t  rain on  ice.  Cells 
were then washed once with 1 ml of PBS. Second-reagent incu- 
bation was  per~bnned in 50  I.tl of streptavidin-PerCp (Becton 
Dickinson & Co., Mountain View,  CA)  conjugated at the con- 
centration indicated by the manufacturer, for  15  rain on ice in 
the  dark.  The  first-step  antibodies were  CD4,  FITC-coupled 
anti-mouse  CD4  (20  p.g/ml;  PharMingen,  San  Diego,  CA); 
CD8,  PE-coupled anti-mouse LyT-2 (20 gg/ml; PharMingen); 
V1314, biotinylated anti-mouse V1314 (20 btg/ml; PharMingen). 
Three-color analysis was performed on 2 ￿  104 viable cells with a 
FACScan  |  (Becton Dickinson & Co.); the stains were plotted on 
a quadruple logarithmic  scale. 
T Cell Prolferation Assay.  The cells were isolated fiom lymph 
nodes and cultured in 96-well plates for 4 d  in IMDM (Siena 
Chemical  Co.,  St.  Louis,  MO)  supplemented  with  2  mM 
t-glutamine. 100  U/ml penicillin, 100 I~g/ml streptomycin (all 
from Sigma Chemical Co.)  and 5% heat-inactivated FCS (Boeh- 
ringer Mannheim Corp., Indianapolis, IN), with serial dilution of 
synthetic peptide.  The cells were incubated in triplicate wells, and 
1 IxCi  of [3H]thymidine was added to the wells during the last 16 h 
of culture. The plates were then harvested and counts per nfinute 
were detemfined by means of liquid scintillation counting. 
Measureme,t  of Ig Isotypes a,ld Cytokines.  Serum lg levels and 
cytokine amount were  detemfined by solid-phase  ELISA  with 
the  use  of a  sandwich  assay. High-bind plates  (Costar  Corp., 
Cambridge, MA) were coated with diflbrent antiisotype and anti- 
cytokine antibodies at l(.I btg/ml in PBS and 50 p.I/well. After in- 
cubation for 24 h at 4~  the wells were washed five times with 
tap water (for isotype ELISA) or PBS. 0.05% Tween 20 (for cyto- 
kine measurement). The plates were blocked with 200 I.d/well of 
PBS, 0.5~  BSA for  1 h at 37~  and then rinsed five times with 
tap water (for isot3.,pe ELISA) or PBS 0.05% Tween 2(7) (for cyto- 
kine measurement). Mouse lg or cytokine standards (50 hal/well) 
at various dilutions starting from  10 I.zg/ml (in PBS, 0.5% BSA) 
and serum samples  or  culture supernatants  were  loaded  m  the 
wells and incubated tbr 24 h at 4~  After washing the wells with 
PBS-Tween or water,  50  btl of annisotype or anticytokine bi- 
otin-coupled secondary  antibodies were  added  for  another  1-h 
incubation at 37~  The wells were then washed six times and in- 
cubated 30 rain with 100 gl of alkaline phosphatase-conjugated 
streptavidin  (Boehringer Mannheim Corp.) at the manufacturer's 
recommended  concentration.  The  developing  substrate  (0.1% 
p-nitrophenyl phosphate)  was added  for at least 30 min at room 
temperature,  and the  plates were  read  with  a  reader  (Hewlett 
Packard  Co.,  Palo Alto.  CA).  IFN-"/ and IL-4 used  as standard 
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rum level was  measured by inhibition ELISA.  After overnight 
coating with the  N1G9  (IgG1) antibody and a  1-h blocking in 
PBS, 0.5% BSA, 0.05% Tween 20, the plates were incubated for 
1 h at 37~  with 50 btl of a mixture of 50% sera and 50% biotin- 
conjugated goat anti-mouse IgG1  antibody (Southern Biotech- 
nology Associates, Birmingham, AL)  at a final concentration of 
0.05  ~g/ml.  After  PBS,  0.05%  Tween  20  washing,  the  plates 
were treated, as previously described, with alkaline phosphatase- 
conjugated streptavidin and revealing substrate. 
Antibodies.  The  isotype-specific antibodies were  as  follows: 
anti-mouse  IgE,  95.3  and  biotin-conjugated anti-mouse  IgE 
(PharMingen); anti-mouse IgM,  R33-42-12  and biotin-conju- 
gated R  33-60; anti-mouse IgG1, biotin-conjugated anti-mouse 
IgG1 (Southern Biotechnology Associates); anti-mouse lgG2b, R 
14-50  and biotin-conjugated goat anti-mouse IgG2b (Southern 
Biotechnology Associates);  anti-mouse IgG3,  2E.6  and biotin- 
conjugated  goat  anti-mouse  IgG3  (Southern  Biotechnology 
Associates); anti-mouse IgG2a  a and IgG2a  ~, purified and biotin- 
conjugated  anti-IgG2a  allotypes  (all  from  PharMingen);  anti- 
IgE  ~, purified anti-total IgE and alkaline phosphatase-conjugated 
anti-IgE  ~  (all  from  PharMingen).  All  of  the  antibodies  were 
kindly provided by K. Rajewsky (Cologne University, Cologne, 
Germany). Purified and biotin-conjugated anti-IFN-7 and anti- 
IL-4 antibodies were purchased from PharMingen, whereas the 
following antibodies used for the standard curves were provided 
by  K.  Rajewsky:  IgG1,  NIG9;  IgE,  12.2;  IgG2b,  D3-13  F1; 
IgG2a  a, 42.1; IgG2a  ~, $43.10; IgM, B1-8; IgG3, $24/63/63. 
Peptide-induced  Thymic  Deletion.  The peptide,  not soluble in 
PBS, was resuspended in water at a concentration of 10 mg/ml. 
Mice were injected i.v. with 100 Ixl ofpeptide solution or 100 ~1 
of water as a control. 
Propidium Iodide Analysis.  106 thymocytes were incubated 30 
min on ice in 1 ml ofS0 ~g/ml propidium iodide, 0.1% sodium 
citrate, 0.1% Triton X-100. Cells were then analyzed by FACS  | 
as described (23). 
Immunolocalization  of the  Apoptotic  Thymocytes.  Fragments of 
thymuses were  frozen in dry ice powder and stored at  -80~ 
5-btm frozen sections were cut and mounted on gelatine-coated 
glass slides. The cryosections were dried at room temperature for 
at least 1 h and fixed in acetone for 5 rain. The terminal deoxy- 
nucleotidyl transferase-mediated  dUTP-biotin nick  end-label- 
ing (TUNEL) method was carried out using the Apoptag  TM  kit 
(Oncor Inc., Gaithersburg, MD).  Briefly, the cryosections were 
incubated at 37~  with terminal transferase enzyme and digoxi- 
genin-dUTP. The apoptotic cells were then detected by staining 
with  20  p~g/ml  of anti-digoxigenin-rhodamine antibody  Fab 
fragments (Boehringer Mannheim Corp.). 
Immunization  Procedure  and  Anti-CD8,  Anti  CD4  Treatment. 
LT2 MC1  galE mutant of Salmonella  typhimurium  strain (24)  was 
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Figure 1.  Thymus T cell population in TCR transgenic mice. Thymocytes from 4-6-wk-old c~/]3 Tg+b  -, Tg+b+-transgenic  mice were stained with 
antibodies specific for CD4 (horizonta! axis) and CD8 (vertical axis,  upper panel) and V[314 variable chain (lower panel).  Nontransgenic and c~/JB-transgenic 
thymocytes were compared.  The lower panel also shows the analysis of V[314 expression in the four thymic subpopulations: CD4+CD8 -  (CD4), 
CD4+CD8 + (DP), CD4  CD8 + (CD8), and CD4-CD8- (DN). 
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fusion  (37  g/liter  of  distilled  water)  at  37~  Bacteria  were 
washed three times with 0.1  M  sodium bicarbonate, pH 8.4, and 
injected intraperitoneally into the mice.  The  first immunization 
was performed with 2.5 X  105 cells in 300 hal and the second one 
with 108 LT2 M1C in 500  I.tl of sodium bicarbonate. The 3.168 
anti-CD8 (25) and the GK1.5 anti-CD4 (26) mAbs were purified 
from supematants by protein G  affinity chromatography (Phar- 
macia Biotech Inc., Piscataway, NJ)  according to recommended 
procedures. 500  #,g of anti-CD8 and anti-CD4 antibodies were 
injected intraperitoneally into mice on days 0,  1, and 2. 
Thymectomy  and  ELISPOT  Assay.  Thymectomy  and 
ELISPOT assay were performed according to  Sjokin et al.  (27) 
and Czerkinsky et al. (28), respectively. 
Results 
Selection  of  the  T  Cell  Clone for  Constructing  Transgenic 
Mice.  The B5  clone was  generated by Bartnes  and Han- 
nestad  (29)  by the  injection of a  y2a  b 1nAb  into  BALB/c 
mice.  The  T  cell is  a  CD4 +,  Thl,  I-Aa-restricted clone, 
and the epitope recognized by B5 TCR  was mapped in the 
CH3  domain  of IgG2a  b  (residues  435-451)  (30).  We  se- 
lected B5 because it has been shown to suppress the Igh-lb 
allotype in vivo (29);  moreover, the choice of an allotype- 
specific  T  cell  allowed  us  to  generate  transgenic  control 
mice that do not express the self-antigen. 
The rearranged ix and J3 chains of the TCR  were cloned 
by  anchored  PCR  (20)  or  RT-PCR,  respectively,  se- 
quenced,  and then  introduced into  the priSE3'  transgenic 
vector (21). Transgenic mice were generated using the two 
XhoI-XhoI  fragments  corresponding  to  the  functionally 
rearranged  TCR  genes  containing  Vix4DA33  (31)  and 
V1314  (32) variable chains (data not shown).  Separate ix and 
J3  chain-transgenic  mice  were  established  by  injecting 
(DBA/2  ￿  BALB/c)F2  fertilized eggs,  and  the  two  lines 
were  then  bred  together  to  produce  mice  expressing the 
complete TCR.  Transgenic  mice were  generated  on  two 
different genetic backgrounds as described in Materials and 
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Figure 2.  Transgenic  thymocyte deletion after peptide injection￿9  lmmunofluorescent staining with the TUNEL  method  of Tg+b+-transgenic mice 
thymic cryosections: (A) noninjected, (B) injected with 100 ~1 of water, and (C) injected with water-resuspended (100 pA) peptide, compared with (D) 
peptide-injected nontransgenic mice. (E) CD4 (horizontal axis) and CD8 (vertical  axis) staining of Tg+b  + mice thymus compared with (~ nontransgenic 
mice after peptide injection￿9  The total thymus cell  number recovered from each mouse was between 80 and 100 million. Bar, 500 bun. 
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Figure  3.  Lymph node T cell popu]ations  in TCP, transgenic mice and specific 
proliferative response in vitro.  (A) Lymphocytes from 4-6-wk-old Tg+b -, Tg+b  +, 
and  nontransgenic  mice were stained with anti-CD4 (horizontal axis), anti-CD8 
(vertical axis) antibodies (upper panel), and anti-V~14  variable chain antibody  (lower 
panel).  Analysis of VIM4 expression  in  the  two  lymph  node  subpopulations, 
CD4+CD8 -  (CD4) and CD8+CD4 -  (CD8), is shown.  (B) Peptide-specific prolif- 
erative response in Tg+b + and Tg+b -  mice was also tested: mesenteric lymph node 
(2 X 10S/well) from Tg+b + (heavy squares), Tg+b -  (light squares) and nontransgenic 
mice cells (solid diamonds), were cultured for 4 d at 37 ~  with the addition  of syn- 
thetic peptide.  Cultures were pulsed with 1 I*Ci of [3H]thymidine for the last 16 h 
and harvested. Incorporation  was measured by means of scintillation counting. 
Methods:  Igh-1J~  (Tg+b -  not expressing the  self-antigen) 
and Igh-P/b (Tg+b +, expressing the self-antigen). 
Thymic T  Cell Populations  in TCR-Transgenic Mice.  V1314- 
expressing T  cells could be followed by the 14.2 mAb (33); 
anti-V[314  staining  showed  that  thymic  V[3  transgene  ex- 
pression was comparable to the pattern  of TCR  expression 
in  normal  animals.  Three  different  populations  were  ob- 
served in the thymus:  high  (CD4  or CD8  single-positive), 
intermediate  (double-positive)  and  low  (double-negative) 
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VJ314-expressing  T  cells  (Fig.  1).  No  thymic  deletion  of 
the transgenic  T  cells was found  as CD4,  CD8,  and  V[314 
triple staining showed  a  slight increase  in the  CD4+CD8 - 
cells of both Tg+b -  and Tg+b + mice, compared with their 
nontransgenic littermates  (Fig.  1). 
Peptide-induced  Apoptosis  of Double-positive  T  Cells.  To 
assess  whether  transgenic  thyrnocytes  were  susceptible  to 
deletion  as  a  mechanism  of tolerance  induction,  we  com- 
pared  the  thymuses  of the  Tg+b +  mice for apoptosis  after injection with  1 mg/100 I*1 of the specific peptide  (30)  or 
water, and noninjected mice (the peptide, not soluble in sa- 
line,  was dissolved in water).  10 h  after injection,  propid- 
ium iodide FACS  |  analysis (23) showed <1% of apoptotic 
cells  in  both  the  noninjected  and  water-injected  mice, 
whereas  10% of the total thymus cell population was apop- 
totic  in  those  injected  with  peptide  (data  not  shown). 
These data were confirmed by immunofluorescent staining 
of  thymus  cryosections  (Fig.  2  C)  using  the  TUNEL 
method  (34).  On sections,  the  preferential  staining  of the 
cortex  is  consistent  with  a  deletion  of double-positive  T 
cells.  An increase  in  the  CD4  and  CD8  double-negative 
subpopulation  was  detected  in  peptide-injected  mice  by 
means of CD4/CD8 immunofluorescence and FACS anal- 
ysis (Fig.  2  E),  indicating that,  if deletion  had  occurred in 
the thymus ofnon-peptide-injected Tg+b + mice, it would 
have also been detected.  We therefore concluded that the 
transgenic  T  cells  are  not  deleted  in  the  thymus  but  re- 
leased into the periphery. 
Lymph  Node  T  Cell  Populations  in  TCR-transgenic  Mice. 
Lymph node single CD4 + and CD8 + subpopulations were 
similar in the Tg+b -, Tg+b +, and control mice. The V~14 
transgene was expressed in "-'70-80% of CD4+CD8 -  cells 
and in 50-70% ofCD8+CD4 -  lymphocytes (Fig. 3 A). To 
determine whether the T  ceils  in the transgenic mice were 
functional, we measured the capacity of lymph node-trans- 
genic T  cells  to proliferate in vitro in response to the spe- 
cific  peptide.  Lymph  node  Tg+b -  T  cells  proliferated, 
whereas Tg+b + cells  did not (Fig. 3 B). 
Transgenic T  Cells are Functional  In  Vivo.  To test whether 
this  nonresponsive  status  of Tg+b +  transgenic  T  cells  ob- 
served in vitro was physiologically important,  self-antigen 
serum  levels  were  measured.  Surprisingly,  IgG2a  b  serum 
levels (Fig. 4 A) were undetectable with ELISA (sensitivity 
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Figure 4.  Serum  levels of IgG2a  b in Tg+b  + mice. (A) IgG2a  b and (B) 
IgG2a  ￿9  serum levels in 4-6-wk-old mice were measured using solid phase 
ELISA. (C) Animals were treated on days 0, 1, and 2 with 500 p~g ofanti- 
CD8-depleting antibody. Serum levels of IgG2a  b in nontreated, PBS- 
treated, and antibody-treated mice were measured by ELISA. 
3  ng/ml),  whereas  IgG2a  ~ levels  were  comparable  with 
those of nontransgenic mice (Fig. 4  B); furthermore, ~/2a  b- 
secreting  cells  from lymph  node  and  spleen  were  consis- 
tently  undetectable  as  estimated  by  the  ELISPOT  assay, 
whereas  60  spot-forming cells/106  cells  were  measured in 
normal animals (data not shown). These results clearly indi- 
cate that transgenic  T  cells  do not become tolerant  in the 
periphery by clonal deletion or by induction of anergy but 
rather regulate the number of y2aLproducing cells. 
As transgenic animals have a relevant CD8+CD4 -  popu- 
lation, a possible involvement of cytotoxic T  cells in deter- 
mining the observed phenotype was tested by injecting an 
anti-CD8-depleting mAb into mice (25): during the 7 d in 
which the CD8 + cells were not detectable in the peripheral 
blood,  no  increase  in  IgG2a  b  serum  levels  was  observed 
(Fig. 4  C), thus suggesting that CD8 + cells  do not play any 
major role.  In contrast,  treatment with anti-CD4 mAb re- 
stored  IgG2a  b  control levels  2  d  after  injection  (data  not 
shown). 
Transgenic  T  Cells are Functional  in  Thymectomized  Tg+ b + 
Mice.  Adult transgenic  mice were thymectomized to in- 
vestigate  whether  only  newly  generated  transgenic  lym- 
phocytes were  involved in  determining  the  phenotype.  If 
this were the  case,  then  IgG2a  b control levels would have 
been restored once newly matured transgenic lymphocytes 
had been excluded. However, 5 mo after thymectomy, no 
increase  in  ~/2a  b  serum  levels  was  observed  (data  not 
shown), suggesting that memory is preserved. 
Altogether,  these  data  indicate  that  transgenic  T  cells 
may be in an undefined functional state in vivo that is not 
measured in vitro by the antigen-specific proliferation assay. 
Transgenic  T  Cells Are  Involved  in  an  IgG2a-to-IgE  Class 
Switch.  On  days  0  and  7,  transgenic  mice  were  immu- 
nized with S.  typhimurium to challenge the immune system 
and increase IgG2a  b serum levels. 3 wk after immunization, 
a  peak  level  of 10  Ixg/ml  of "y2a  b protein  was  reached, 
which was almost 60 times lower than that reached in the 
control mice  (Fig.  5, A  and  B).  Interestingly,  as the  other 
isotypes and the IgG2a  a were unaffected (Fig. 6), IgE serum 
levels were five times higher than in the nontransgenic ani- 
mals  (Fig.  7  A).  4  wk  after  immunization,  a  decrease  in 
A  B 
1000 ]  [] Tg  "b+  T  1  I~Tg'l'b+  ~L_  I 
￿9  .~ .....  0 
0  1  2  345  6  7  8  9  0  1  2  3  4  5  6  7  8  9 
immunization  immunization 
Figure 5.  IgG2a  b serum levels during an immune response￿9  Transgenic 
mice were immunized on days 0 and 7 with S. typhimurium (arrows). (.4) 
Nontransgenic and  (B) transgenic mice IgG2a  b total serum levels, fol- 
lowed from 0-9 wk during immune response. IgG2a  b serum levels re- 
mained 60 times lower in transgenic compared with control mice. 
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Figure 6.  Total Ig serum levels during the im- 
mune response. Mice were immunized on days 0 
and 7 with S.  typhimurium. Isotype serum levels 
were followed for 9 wk during the immune re- 
sponse. No significant  differences were observed 
in transgenic  and control animals. 
IgG2a  b was  associated with an increase in IgE levels. The 
increased IgE in the transgenic (Tg+b  +)  (Igh-1  a/b) were all 
of the  b  allotype  (Fig.  7  B),  suggesting that  they  derive 
from IgG2aCpositive cells.  A  similar response was also ob- 
served  with  immunization of the  transgenic  mice  with 
nonmicrobial  protein antigens (data not shown). 
The State of Transgenic T  Cell Responsiveness  Is Changed af- 
ter  Immunization.  The  immunization  of  the  transgenic 
mice  with  S.  typhimurium  gave  rise  to  another important 
finding aside from the increase in IgE serum levels. Lymph 
node  cells  from  Salmonella-immunized  transgenic  mice 
could proliferate in vitro in response to the specific peptide 
(Fig. 8 A) and produce IFN-~/ (Fig. 8  B). As late as  13 wk 
after immunization, the transgenic T  cells still retained their 
different activation state,  as  shown by the  capacity of the 
transgenic T  cells to proliferate and produce lymphokines 
in vitro. 
Discussion 
As the mechanisms of tolerance induction to circulating 
self constituents are still not clearly defined, we generated a 
transgenic mouse model with a TCR specific for the serum 
protein IgG2a  b.  The original T  cell clone from which the 
TCtL-c~ and -[3 chains were derived was chosen because it 
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Figure  7.  Total IgE and lgE  b serum levels during the immune re- 
sponse. (A) Mice were immunized on days 0 and 7 with S. typhimurium. 
Transgenic  mice IgE total serum levels followed for 9 wk were compared 
with levels from control mice. (B)  Comparison of IgE  b and total IgE 
(IgET) serum levels  at the peak of the response (4-5 wk after immuniza- 
tion) in Tg+b  + and Tg-b  + mice. 
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Figure  8.  Peptide-specific  proliferative response and cytokine produc- 
tion in immunized mace. (A) Peptide-specific proliferative response in 
immunized Tg+b  + mice. 5 wk after immunization, the lymphocytes  (2 ￿ 
10S/well) of Tg+b  + mice (open squares) and  nontransgenic mice (solid 
squares) were cultured with the synthetic peptide for 4 d at 37~  1 IxCi/ 
well of [3H]thymidine was added for the last 16 h of incubation. The cul- 
tures were then harvested and their incorporation measured by means of 
scintillation counting. (B) Cytokine production by transgenic lymph node 
T cells. IFN-  7 and IL-4 production was investigated by ELISA 3 d after 
in vitro culturing with the synthetic peptide. 
had  been  shown  to  suppress  the  Igh-lb  allotype  in  vivo 
(29).  Further,  this allotype-specific T  cell clone allowed us 
to generate transgenic control mice that did not express the 
self-antigen.  Thus, transgenic mice were produced on two 
different genetic backgrounds: Igh-I  a/a and Igh-1 a/b. 
Thymic deletion has been described in TCP,-transgenic 
mice specific for the blood-borne self-antigen C5 (13), and 
thymic or peripheral tolerance was observed with other se- 
rum proteins expressed as transgenes  (10,  11). Surprisingly, 
in our transgenic model, peripheral  T  cell activity was ob- 
served rather than T  cell tolerance, which is consistent with 
a previous finding from Bogen et al.  (15) also showing pos- 
itive selection for idiotype-specific transgenic T  cells.  How- 
ever,  in  this  model,  given  the  small  number  of idiotype- 
expressing B cells,  the influence of the T  cells on the fate of 
the B  cells could not be followed. The choice of an antial- 
lotype T  cell allowed us to investigate the fate of the B cells 
after T  cell interaction. 
We have shown that anti-Ig-specific T  cells are not deleted 
in the thymus and undergo positive selection on H-2  a hap- 
lotype.  Although  the  small  amount  of circulating  IgG2a  b 
(below the level of detection) may have been insufficient to 
reach  the  thymus  and  be  presented  to  transgenic  T  cells, 
there was no evidence of negative selection in the thymus 
of immunized mice when IgG2a  b serum levels reached  10 
Ixg/ml (data not shown). On the contrary, the skew toward 
CD4+CD8 -  cells  (35) is greater in Tg+b + mice expressing 
the  self-antigen.  One  of the  parameters  that  controls  thy- 
mocyte  selection  is  related  to  the  number  of TCRs  en- 
gaged with peptide-MHC  complexes, with negative selec- 
tion occurring when this number is high (high avidity) and 
positive selection occurring when this number is low (low 
avidity)  (36).  As Igs are not easily processed and presented 
(37), we can assume that the low avidity necessary for posi- 
tive  selection  is  attributed  to  the  low  density of peptide- 
MHC molecules on the surface of selecting cells. We cannot 
exclude  that the  transgenic  T  cells  express  different densi- 
ties  of the  transgenic  TCR  because of expression  in some 
ceils  of a second TCR  using the  transgenic  [3 chain and a 
rearranged  endogenous  oL  chain  (38).  High  density  cells 
would  have  the  highest  avidity  for  the  target  and  might 
have been deleted in the thymus, leaving only low avidity 
cells  emigrating in the periphery. Alternatively, only a par- 
ticular type of cell may be involved in Ig presentation  and 
positive  selection.  If, as proposed in  the  literature  (39),  B 
cells  are the principal Ig APC in the thymus, their number 
might be too low to induce negative selection. 
Injection of specific peptide  was found to lead to dou- 
ble-positive  cell  deletion,  which  may be  explained  by ei- 
ther an increase in peptide density in the thymus or the in- 
volvement  of  APC  different  from  the  selecting  cells 
normally used. 
Tg+b +  mice have very low or undetectable  IgG2a  b se- 
rum levels, and 72a  b secreting ceils are not detectable in ei- 
ther lymph nodes or spleen.  This indicates  that transgenic 
T  cells  do not become tolerant in the periphery by means 
of clonal  deletion  or the  induction  of anergy,  but  instead 
regulate the number of72a  b cells.  Because the b allotype of 
IgG2a appears to be easily suppressed  (40, 41),  it might be 
thought that  the  lack  of tolerance  of anti-b  allotype-spe- 
cific  T  cells  could  be  a  special  case.  Nevertheless,  it  has 
been shown that in mice transgenic for an Ig anti-IgG2a of 
the a allotype, the transgenic B  cells  do not become toler- 
ant even at 50  Ixg/ml of IgG2a  a (42).  Thus,  this feature  is 
not restricted to the b  allotype and seems to be a common 
characteristic ofanti-Ig-specific lymphocytes. 
The activity ofIg-specific transgenic T  cells could not be 
investigated in vitro by means of the proliferation function 
or  lymphokine  secretion  because  these  cells  did  not  re- 
spond to the specific peptide; surprisingly, the transgenic T 
cells  did proliferate and produce IFN-7 after immunization 
with  Salmonella.  The  presentation  of self-Ig determinants 
has  been  investigated  by  Rudensky  and  Yurin  (37)  and 
Bikoff and Eckhardt  (43);  their  results  suggest that B  cells 
are the major cell type presenting Ig because dendritic cells 
and macrophages are inefficient.  We thus assume that,  be- 
fore immunization,  it is the ~/2ab-positive cells  that mainly 
present  the  CH3  domain of their  Ig, and this  determinant 
may not be available for other APC. After interaction with 
B cells,  the T  cells were not anergized in vivo, though they 
were not able to proliferate in vitro. 
T  cell activity was  confirmed in vivo by the  analysis  of 
thymectomized mice: if the T  cells had been deleted or an- 
ergized,  72a  b serum levels would have increased given the 
absence of newly differentiated  transgenic  T  cells,  but this 
was  not  the  case.  The  T  cells  remained  functional  for  at 
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Figure 9.  Fate of  B cells during the immune response. Antigen-specific 
T cells interact with IgM  + B cells that induce their maturation and class 
switch. After this process, the IgM  + B cells become IgG2ab-expressing 
cells that can present epitopes of ",/2a  b and interact with allotype-specific 
transgenic T cells. A further class switch of the B cell is induced by this 
interaction. It cannot be excluded that this process induces B cell death. A 
possible involvement of non-B APC must be considered. 
least  5  mo  after  thymectomy,  thus  indicating that  T  cell 
memory was preserved. 
After  immunization  with  Salmonella, the  increase  in 
IgG2a  b serum levels made  it available for other APC  that 
could now present the IgG2a  b epitope to the transgenic T 
ceils.  The  signal given by non-B  APC  could drive the  T 
ceils to a different functional state, which could then be in- 
vestigated  in  vitro  by  peptide-specific  proliferation  and 
lymphokine secretion.  Once  the T  cells reached this state 
of maturation, they preserved it for at least 13 wk. 
The fate of the B  cells in immunized transgenic mice was 
also  followed  during  the  immune  response;  the  y2a  b  Igs 
reached a peak of 10  Ixg/ml 3  wk after immunization and 
started decreasing at 4  wk.  At the same time,  the level of 
IgE increased until it was five times higher than that in the 
nontransgenic animals. Interestingly, this increase is ascrib- 
able to IgE of the b allotype, indicating that IgEb-positive B 
cells might  derive from  IgG2ab-positive cells.  To  explain 
this observation, we propose that during the immune chal- 
lenge,  when  IgM-expressing B  cells become  IgG2a  b pro- 
ducers, epitopes of the ~/2a  b protein are presented by B  cells 
to antiallotype transgenic T  cells (Fig. 9). It can be hypoth- 
esized that the outcome of this interaction is the induction 
of a  further  switch  to  IgE;  this is  consistent with  the  ge- 
nomic  organization  of  the  Ig  locus,  the  ~  gene  being 
downstream  to  the y2a gene.  However,  at this point,  we 
cannot  distinguish  isotype  switching  of activated B  cells 
from differentiation (and secretion) of previously generated 
memory cells. In addition, since it has not been proven that 
memory B  cells cannot switch to others isotypes, this might 
be the system to investigate this problem. Nevertheless, the 
possibility that B  cells die after antiallotype transgenic T  cell 
interaction cannot be formally excluded. 
Given that transgenic T  cells are not deleted in the thy- 
mus and are functional in the periphery, all of these find- 
ings indicate that  Ig-specific T  cells could exist in normal 
individuals and may represent a  late-acting form of T  cell 
help for the regulation of the IgG2a-to-IgE class switch. 
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